Illumina, Inc. (ILMN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Diagnostics & Research Branche. Der Hauptsitz des Unternehmens ist in San Diego, CA, United States. Der aktuelle CEO ist Jacob Thaysen.
ILMN hat IPO-Datum 2000-07-28, 8,970 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $19.93B.
Illumina, Inc. is a global leader in sequencing and array-based solutions for genetic and genomic analysis, founded in 1998 and headquartered in San Diego, California. The company develops and manufactures instruments and consumables for genetic analysis, along with genotyping, sequencing, and cancer detection testing services that enable genomic adoption across research, clinical, and commercial markets. Its products serve diverse applications including life sciences research, oncology, reproductive health, agriculture, and emerging segments, with customers spanning academic institutions, government laboratories, hospitals, pharmaceutical firms, biotechnology companies, and molecular diagnostic laboratories. Illumina distributes its offerings through direct sales channels in North America, Europe, Latin America, and the Asia-Pacific region, as well as through partnerships with life-science distributors across multiple international markets. The company generates revenue through instrument sales, consumable products, genotyping and sequencing services, instrument service contracts, and licensing agreements.
